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Background: Buprenorphine is a partial µ-opioid receptor agonist used for maintenance treatment 
of opioid dependence. Because of the partial agonism and high receptor affinity, it may precipitate 
withdrawal symptoms during induction in persons on full µ-opioid receptor agonists. Therefore, 
current guidelines and drug labels recommend leaving a sufficient time period since the last full 
agonist use, waiting for clear and objective withdrawal symptoms, and reducing pre-existing full 
agonist therapies before administering buprenorphine. However, even with these precautions, 
for many patients the induction of buprenorphine is a difficult experience, due to withdrawal 
symptoms. Furthermore, tapering of the full agonist bears the risk of relapse to illicit opioid use.
Cases: We present two cases of successful initiation of buprenorphine treatment with the 
 Bernese method, ie, gradual induction overlapping with full agonist use. The first patient began 
buprenorphine with overlapping street heroin use after repeatedly experiencing relapse, with-
drawal, and trauma reactivation symptoms during conventional induction. The second patient 
was maintained on high doses of diacetylmorphine (ie, pharmaceutical heroin) and methadone 
during induction. Both patients tolerated the induction procedure well and reported only mild 
withdrawal symptoms.
Discussion: Overlapping induction of buprenorphine maintenance treatment with full µ-opioid 
receptor agonist use is feasible and may be associated with better tolerability and acceptability 
in some patients compared to the conventional method of induction.
Keywords: subutex, suboxone, heroin, opiate, substitution
Introduction
Buprenorphine is a partial µ-opioid agonist and κ-opioid antagonist used for main-
tenance treatment of opioid dependence (OMT). It is as effective as methadone in 
suppressing opioid use and is slightly less effective in retaining patients in treatment.1 
Buprenorphine has potential advantages over methadone, including a lower risk of over-
dose due to the partial agonism and the associated “low ceiling effect” for respiratory 
depression, fewer pharmaceutical interactions, and absence of corrected QT interval 
(QTc)-prolongation.2–4 However, because buprenorphine replaces other opioids at the 
µ-receptor due to its high affinity, the partial agonism at the µ-opioid receptor may 
precipitate severe withdrawal in persons regularly using opioids.5 Therefore, guidelines 
on buprenorphine induction in OMT and drug labels recommend consideration of the 
nature of opioid dependence (ie, long- or short-acting opioid), its degree, and the time 
since last opioid use:4,6,7 physicians should leave sufficient time between last use of opioid 
agonist and buprenorphine. This time depends on the opioid used and ranges between 
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4 (heroin) and 36–48 hours (methadone). Moreover, waiting 
for observable opioid withdrawal symptoms before starting 
buprenorphine is recommended. A switch of the substitute 
from methadone to buprenorphine requires prior tapering of 
methadone to a daily dose of 30–40 mg.8
Clinical experience shows that despite these precautions, 
the induction of buprenorphine can precipitate severe opioid 
withdrawal. In addition to the discomfort, this may lead to 
treatment dropout or relapse with full opioid agonists. Pre-
cipitated withdrawal and the complicated induction process 
may result in differences between buprenorphine and metha-
done with regard to treatment retention in the first 2 weeks.9
Between 40% and 60% of buprenorphine-maintained 
persons concomitantly use full µ-receptor agonists.10–12 
According to patients’ accounts and experimental studies, this 
use is not associated with opioid withdrawal but attenuated 
subjective opioid effects such as euphoria.13 The attenuation 
persists for some days after termination of buprenorphine 
use. The likely explanation is the higher opioid receptor 
binding capacity of buprenorphine. Other opioid agonists 
and their active metabolites can replace only a small fraction 
of buprenorphine at the receptor. Moreover, because of its 
low dissociation constant, buprenorphine separates slowly 
from the receptor once it is bound.14 The slow association/
dissociation kinetics allow for 72-hour dosing intervals in 
buprenorphine treatment.4,15 Because of the high µ-opioid 
receptor affinity, buprenorphine can replace a full µ-agonist 
at the receptor while at the same time providing less µ-opioid 
effects.16
Resnick et al17 showed that repetitive administration of 
the µ-antagonist naloxone quickly leads to a maximum of 
withdrawal symptoms that decline afterward despite contin-
ued naloxone application. This phenomenon was used in the 
1980s in the development of rapid withdrawal procedures.18 
Furthermore, it was shown that a very small dose of 0.2 
mg buprenorphine intravenous (iv) did not produce opioid 
withdrawal in methadone-maintained individuals.19
From this, we developed the following hypotheses: 1) 
Repetitive administration of very small buprenorphine doses 
with sufficient dosing intervals (eg, 12 hours) should not 
precipitate opioid withdrawal. 2) Because of the long receptor 
binding time, buprenorphine will accumulate at the receptor. 
3) Over time, an increasing amount of a full µ-agonist will be 
replaced by buprenorphine at the opioid receptor.
Hence, overlapping induction of buprenorphine with 
ongoing use of street heroin or maintenance on high doses of a 
full µ-agonist should be possible without precipitating severe 
opioid withdrawal. We present two cases in which we tested 
this procedure, termed the Bernese method. In both patients, 
we used sublingual buprenorphine, as the buprenorphine/
naloxone combination is not available in Switzerland. We 
first introduced this method in 2010, and described the initial 
treatment of the first case in German.20 The second case has 
never been published before. We have successfully applied 
the Bernese method in a number of patients since. Clinical 
treatment was conducted in agreement with the patients, 
and both patients consented to the publication of their data 
in anonymized form.
Case 1
The patient grew up in an unremarkable middle-class fam-
ily. At the age of 12, she was sexually abused and developed 
post-traumatic stress disorder. At the age of 15, she began 
using various substances (psilocybin, 3,4-methylenedioxy-
methamphetamine, cocaine, cannabis, and, sporadically, 
heroin). At the age of 18, she experienced a major depressive 
episode with a suicide attempt. She then started suffering 
from bulimia, which remitted at age 23.
Preceding a job-related stay in Central America, she used 
heroin for several weeks. During the stay, she was unable 
to obtain heroin and began using crack-cocaine, quickly 
developing a severe dependence. Back in Switzerland, she 
successfully managed to stop crack-cocaine, but reinitiated 
heroin use. After several months, she opted for buprenorphine 
treatment but experienced the induction-associated symptoms 
as very stressful.
She stabilized during treatment, tapered buprenorphine 
and abstained from opioids for several months before initiating 
sporadic use of heroin again. At the age of 30, when she entered 
our outpatient treatment, she sniffed 3 g of street heroin daily.
Conventional induction
The patient was ordered to return in the morning. She had 
then abstained from heroin for more than 8 hours and showed 
distinct symptoms of withdrawal (rhinorrhea, mydriasis, and 
stomach cramps).
Buprenorphine was started at 0.4 mg sublingually, and 
the same dose was administered four times with an interval 
of 30 minutes. Starting with the first and increasing with 
each further administration, she felt worse and suffered from 
diarrhea. She experienced trauma-related flashbacks and 
showed severe anxiety and dissociative thinking. Her state 
did not improve with two further doses of 8 mg buprenor-
phine. We then administered 50 mg of promazine po, which 
brought some relief, and after 8 hours of surveillance she 
had improved sufficiently to return home.
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Bernese method
After 2 weeks, the patient stopped taking buprenorphine and 
reinitiated sniffed heroin use. A week later, she presented 
herself again with the wish for buprenorphine treatment, 
but was afraid of being unable to tolerate the induction pro-
cess and the related symptoms. We suggested overlapping 
buprenorphine induction with the Bernese method (ie, start 
with a low dose of 0.2 mg buprenorphine overlapping with 
heroin use, small daily dose increases, and abrupt cessation 
of heroin use at sufficient dose). Furthermore, we offered her 
the support of a physician (via text message) to flexibly adapt 
dosing. Buprenorphine dosing and use of street heroin were 
noted (Table 1). The patient tolerated this induction process 
much better than the conventional induction.
She was stable with 12 mg/d buprenorphine. Throughout 
further treatment she stopped buprenorphine several times, 
used heroin, and afterward reinitiated buprenorphine treat-
ment with the Bernese method. However, after these short 
disruptions, she increased buprenorphine dosing more rap-
idly. She then developed a major depressive episode and was 
started on 20 mg/d escitalopram and psychotherapy. With this 
treatment, she stabilized further and abstained from heroin 
for 2.5 years.
Because of the desire for complete abstinence, she then 
wanted to stop buprenorphine and initiate naltrexone treatment 
to reduce opioid craving. However, she was worried about the 
first week after cessation of buprenorphine, where naltrexone 
should not be administered according to the drug label.
Overlapping induction of a full antagonist
We assumed that naltrexone could be initiated analogous 
to the overlapping induction of buprenorphine. Prelimi-
nary data suggest that very low naltrexone doses during 
µ-agonist treatment may not be associated with reduced 
analgesic efficacy.21 However, naltrexone tablets available 
in Switzerland contain a rather large dose of 50 mg drug. 
After tapering of  buprenorphine to 2 mg/d, the patient 
started with small amounts of naltrexone scratched off from 
a tablet and increased the dose daily. She did not develop any 
withdrawal symptoms or craving, stopped buprenorphine, 
and increased naltrexone to 25 mg/d. After several months, 
she stopped naltrexone and has since been abstinent for an 
ongoing period of 3 years and 3 months.
Case 2
After using heroin for several years and unsuccessful 
treatment attempts with methadone, the patient entered 
 heroin-assisted treatment (HAT) at the age of 49. In addition 
to heroin dependence, he fulfilled International  Classification 
of Diseases-10 criteria for cocaine and tobacco dependence. 
He suffered from mild chronic obstructive pulmonary disease, 
chronic hepatitis C-infection, and recurrent thrombosis due to 
groin injection. Furthermore, the patient had a long history 
of substance-related crime and imprisonment. Throughout 
6 years in HAT, he completely stopped using street heroin, 
reduced cocaine use to once per month, and entered a job 
rehabilitation program. At this point, he received 200 mg 
diacetylmorphine (DAM; ie,  pharmaceutical heroin) iv twice 
daily, and 40 mg of methadone to avoid nighttime withdrawal 
symptoms. Because he wanted to stop iv  injections, iv DAM 
was switched to oral tablets at the equivalent dose of 400 mg 
twice daily. After another 2 months without using nonpre-
scribed opioids, the patient desired a less rigid therapeutic 
setting (HAT entails twice daily medication dispensing 365 
days per year). We suggested switching to buprenorphine. 
Because of fears that the guideline-recommended reduction 
of the full agonist dose prior to switching might lead to a 
destabilization, we suggested induction with the Bernese 
method.
Overlapping induction of buprenorphine 
with maintenance on full µ-agonists
At first administration of buprenorphine, the patient had been 
on a stable oral maintenance dose of 40 mg methadone and 
800 mg DAM per day for 2 months. It is important to note 
that we did not grant take-home dosages for DAM tablets, 
but substituted these with methadone. The patient received 
methadone instead of DAM when he could not attend on-site 
dispensing. He completed the short opioid withdrawal scale 
(SOWS) daily. The SOWS is a ten-item questionnaire rating 
withdrawal symptoms on a scale of 0–3, yielding a maximum 
score of 30.22 Another question on opiate craving answered 
likewise was added. Furthermore, every third day the patient 
Table 1 Buprenorphine dosing and use of street heroin in case 1
Day Buprenorphine (sl) Street heroin (sniffed)
1 0.2 mg 2.5 g
2 0.2 mg 2 g
3 0.8+2 mg 0.5 g
4 2+2.5 mg 1.5 g
5 2.5+2.5 mg 0.5 g
6 2.5+4 mg 0
7 4+4 mg 0
8 4+4 mg 0
9 8+4 mg 0
Abbreviation: sl, sublingual.
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completed visual analog scales related to general mental state 
and feeling stressed, relaxed, and nervous.
We began with a dose of 0.2 mg buprenorphine sublin-
gually, which was well tolerated. The next day, the dose was 
increased to 0.4 mg twice daily. We decided to dose twice 
daily in the beginning as the effect of buprenorphine is 
shorter at lower doses and switched to once-daily dosing at 
2 mg/d. Buprenorphine was principally increased by 0.4 mg/ 
d up to a dose of 3.4 mg, then we increased the daily dose 
by 20%–30%. The patient tolerated buprenorphine induction 
very well but reported mild opioid withdrawal symptoms on 
day 8 at 3 mg/d and day 11 at 4.8 mg/d (Table 2). At 6 mg/d 
on day 14, the patient went on a 5-day vacation and was 
switched to 180 mg/d methadone (as DAM tablets were not 
available as take-home medication), while the buprenorphine 
dose remained unchanged. During days 13–16, he reported 
slightly stronger withdrawal symptoms, although they were 
still mild to moderate (maximum score of 7 in the SOWS). 
Days 15 and 16 were the only days during induction on which 
he reported any opiate craving (moderate). Unfortunately, he 
did not complete the SOWS on days 17–19 but retrospectively 
reported a complete remission of withdrawal symptoms dur-
ing that time. When he returned 1 day later than planned on 
day 19, he did not show signs of withdrawal. On day 22, we 
increased the buprenorphine dose again. The patient did not 
show any substantial withdrawal symptoms thereafter. One 
day after reaching the target dose of buprenorphine 24 mg/d, 
all full agonists were abruptly and completely stopped at day 
29 without any symptoms of opioid withdrawal. The patient 
has now been on buprenorphine treatment for an on-going 
period of 7 months, abstaining from any additional substance 
use. Figure 1 illustrates SOWS scores in relation to daily 
doses of buprenorphine and combined full agonists. For the 
latter, we calculated methadone equivalent daily doses by 
using the following ratio: oral DAM:methadone 8:1.23
Discussion
The two case reports illustrate that buprenorphine main-
tenance can be induced by overlapping with street heroin 
use or OMT with high-dosed full µ-agonists. Both patients 
tolerated the induction well and experienced only very mild 
opioid withdrawal and craving. Twice, the first patient had 
experienced the conventional method of buprenorphine 
induction (ie, induction after more than 4 hours since using 
street heroin and in the presence of clear objective symptoms 
of withdrawal) as very difficult. She reported substantially 
fewer symptoms with the Bernese method.
While the duration until stable buprenorphine dosing may 
be longer than with the conventional method, the Bernese 
method of overlapping induction may have considerable 
advantages. It may be helpful for patients fearing withdrawal 
or experiencing severe symptoms during conventional induc-
tion. It may be associated with fewer and less severe opioid 
withdrawal symptoms. Furthermore, it is no longer neces-
sary to wait for these before induction. In addition to the 
discomfort, opioid withdrawal may lead to dropout during the 
induction process. In fact, the slightly better treatment reten-
tion with methadone compared to buprenorphine seems to be 
related to higher dropout rates during the first 2 weeks.9,24 In 
our experience, some patients are deterred from buprenor-
phine treatment because they fear these symptoms. Moreover, 
providers may be reluctant to use buprenorphine due to the 
complex conventional induction method. With overlapping 
induction, buprenorphine can be initiated directly, indepen-
dent of last opioid use and type of full agonist used. This is 
particularly important considering the repeated cycling in 
and out of treatment observed in OMT.25
The Bernese method may also be beneficial when a switch 
to buprenorphine is desired for patients maintained on a full 
µ-agonist such as methadone, slow-release oral morphine 
sulfate, or DAM. With the conventional induction method, 
tapering of the full µ-agonist, for example to 30–40 mg 
methadone per day, is recommended before buprenorphine 
is initiated.8 Furthermore, it is again necessary to wait for 
objective signs of withdrawal.4 Both prerequisites do not 
apply with the  Bernese method: buprenorphine can be 
increased gradually with overlapping use of the full agonist 
maintenance dose. Once the target dose is reached, the full 
agonists can be stopped abruptly. Hess et al26 have previously 
described a method of switching from doses between 70 
and 100 mg methadone, but used transdermal patches and 
a quicker scheme of dose increases. In our clinical experi-
ence, this scheme can also lead to substantial withdrawal 
symptoms. More research into these methods is necessary 
to investigate tolerability and symptomatology.
Comparing both our cases, it is noteworthy that the dose 
increase in case 2 was done slower and in smaller steps. This 
cautious strategy was chosen for two reasons. First, the patient 
was on high doses of full µ-agonists, likely increasing the 
danger of precipitated withdrawal compared to patient 1 who 
used street heroin containing an unknown, but most probably 
lower, full µ-agonist dose. Second, as patient 2 had stabilized 
well during treatment with full µ-agonists, we did not want 
to jeopardize the improvements by inducing buprenorphine 
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Table 2 Opioid doses, withdrawal symptoms, cravings, and mental state in case 2
Day BUP 
(mg)
DAM 
(mg)
MET 
(mg)
Full 
agonist 
MEQDD 
(mg)a
SOWS 
score
Withdrawal symptoms 
(SOWS)
Cravingb Stressc Overallc Relaxedc Tensec Remarks
1 0.2 800 600 160 0 0
2 0.4+0.4 800 40 140 1 Mild feelings of coldness 0
3 0.8+0.4 800 40 140 0 0 5 84 74 15
4 1.2+0.4 800 40 140 0 0
5 2 800 40 140 0 0
6 2.4 400 80 130 0 0 15 64 57 44
7 2.8 800 40 140 0 0
8 3 800 40 140 3 Mild feelings of coldness, mild 
runny eyes, mild yawning
0
9 3.4 800 40 140 1 Mild runny eyes 0 18 85 76 6
10 4 800 40 140 2 Mild feelings of coldness, mild 
yawning
0
11 4.8 800 80 180 3 Mild feelings of coldness, 
moderate yawning
0
12 6 800 60 160 0 0 5 78 76 4
13 6 800 40 140 1 Mild runny eyes 0
14 6 400 90 140 3 Mild feelings of coldness, mild 
yawning, mild runny eyes
0 Morning: last 
medication 
dispensing 
before 
vacation 
15 6 0 180 180 7 Moderate feelings of coldness, 
mild runny eyes, mild aches 
and pain, moderate sleeping 
problems, mild yawning
2 35 80 81 24 Vacation
16 6 0 180 180 5 Mild feelings of coldness, mild 
runny eyes, mild aches and pain, 
moderate sleeping problems
2 Vacation
17 6 0 180 180 Missing Missing Vacation
18 6 0 180 180 Missing Missing 20 73 79 26 Vacation
19 6 0 80 80 Missing Missing Afternoon: 
first 
medication 
dispensing 
after vacation 
20 6 0 120 120 0 0
21 6 400 80 130 0 0 15 80 73 26
22 7.2 400 40 90 0 0
23 8.8 400 80 130 0 0
24 10.8 800 40 140 0 0 5 94 94 6
25 13.2 400 40 90 0 0
26 16 800 40 140 0 0
27 20 400 60 110 0 0 7 95 92 3
28 24 800 40 140 0 0
29 24 0 0 0 1 Mild yawning 0 Cessation of 
full agonists, 
diarrhea in 
the morning
30 24 0 0 0 0 0 8 93 84 16
31 24 0 0 0 0 0
32 24 0 0 0 0 0
33 24 0 0 0 0 0 9 85 85 15
Notes: aFull agonist (DAM + MET) MEQDD (conversion ratio DAM:methadone 8:1). b0= none, 1= mild, 2= moderate, 3= severe. cScores from visual analogue scale (0–100).
Abbreviations: BUP, sublingual buprenorphine; DAM, oral diacetylmorphine tablets; MET, oral methadone; SOWS, short opioid withdrawal scale; MEQDD, methadone 
equivalent daily dose.
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too rapidly. Taken together, our cases can be regarded as 
representative of the wide spectrum of opioid-dependent 
persons, from sniffers of street heroin on one hand to users 
of high doses of full µ-agonists on the other.
Several questions remain open and need to be addressed 
in systematic studies. The Bernese method should be directly 
compared to conventional induction with randomized study 
designs to determine whether it is generally associated with 
better tolerability. Such studies could also investigate whether 
there is an impact of the induction process on the outcome of 
further OMT, in particular cycling in and out of treatment, or 
whether there are subpopulations of patients for which a spe-
cific induction procedure is preferable. Other issues concern 
the ideal starting dose for buprenorphine, the optimal dose 
increase scheme, and whether this is influenced by blood levels 
and type of full µ-agonist used. It is unclear whether there are 
critical thresholds in buprenorphine dosing that may lead to 
pharmacodynamic changes. Our second patient was kept on 
a daily dose of 6 mg buprenorphine for 10 days, because we 
did not want to increase the dose without medical supervision 
during his vacation. He experienced the strongest, albeit still 
mild, symptoms with buprenorphine doses of 3–6 mg.
Likewise, in pre-existing OMT, it is unknown which 
buprenorphine dose allows cessation of the full µ-agonist 
without producing opioid withdrawal. This dose is likely 
determined by the dose of the full agonist used in OMT. 
Future studies should collect data on blood levels of 
buprenorphine and full agonists.
Our cases illustrate that overlapping induction of buprenor-
phine while being on full µ-agonists is feasible. We hope to 
stimulate more research in this area, which will, ideally, lead to 
a better tolerable, more patient-oriented induction of buprenor-
phine treatment, and diversification of opioids in OMT.
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